Inhibition of NF-κB in cancer cells converts inflammation- induced tumor growth mediated by TNFα to TRAIL-mediated tumor regression  by Luo, Jun-Li et al.
A R T I C L E
Inhibition of NF-B in cancer cells converts inflammation-
induced tumor growth mediated by TNF to TRAIL-mediated
tumor regression
Jun-Li Luo,1 Shin Maeda,1 Li-Chung Hsu,1 Hideo Yagita,2 and Michael Karin1,*
1Laboratory of Gene Regulation and Signal Transduction, University of California, San Diego, 9500 Gilman Drive,
La Jolla, California 92093
2 Department of Immunology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan
*Correspondence: karinoffice@ucsd.edu
Summary
We used an experimental murine cancer metastasis model in which a colon adenocarcinoma cell line generates lung
metastases, whose growth is stimulated in response to injection of bacterial lipopolysaccharide (LPS), to investigate the
role of NF-B in inflammation-induced tumor growth. We found that LPS-induced metastatic growth response in this model
depends on both TNF production by host hematopoietic cells and NF-B activation in tumor cells. Inhibition of NF-B in
both colon and mammary carcinoma cells converts the LPS-induced growth response to LPS-induced tumor regression.
The latter response is TNF-independent, but depends on another member of the TNF superfamily, TRAIL, whose receptor
is induced in NF-B-deficient cancer cells.
Introduction and Kohn, 2001). Whereas certain cytokines and chemokines
promote cancer cell proliferation and survival, others can inhibit
tumor growth and kill cancer cells (Coussens and Werb, 2002;Invasion and metastasis are the main clinical phenomena that
distinguish malignant from benign tumors, and are the leading Dunn et al., 2002). In addition to deregulated cell growth and
survival, many tumors have acquired the ability to subvert im-causes of death in cancer patients. Accumulating evidence sug-
gests that tumor progression is governed not only by genetic mune and inflammatory responses to their benefit (Pollard,
2004). It is therefore of great importance to identify the molecularchanges intrinsic to the cancer cell (Moody et al., 2002; Steeg,
2003), but also by epigenetic and environmental factors (Cous- mechanisms through which the immune/inflammatory system
promotes tumor cell proliferation, survival, and invasiveness assens and Werb, 2002; Pollard, 2004). Chronic infection and the
ensuing inflammation are considered to be some of the most well as those responsible for tumor cell killing. A better under-
standing of these mechanisms may eventually lead to develop-important epigenetic and environmental factors contributing to
tumorigenesis and tumor progression (Coussens and Werb, ment of new therapeutic strategies that will allow conversion of
the tumor-promoting effect of the immune/inflammatory system2002; Pollard, 2004). Although the adaptive immune system
reduces tumor incidence through immune-surveillance mecha- to a strong tumoricidal effect. Using a mouse model of inflam-
mation-induced tumor growth, we explored this possibilitynisms (Dunn et al., 2002), the innate immune system can pro-
mote tumor development and progression through inflamma- through the manipulation of NF-B activity within the cancer
cell.tion-dependent mechanisms (Coussens and Werb, 2002). It was
also observed that bacterial infection following surgery can pro- The NF-B family of transcription factors plays a central role
in regulation of immune and inflammatory responses, apoptosis,mote growth of metastases in experimental animals and human
patients (Harmey et al., 2002; Pidgeon et al., 1999; Taketomi and oncogenesis (Baldwin, 2001; Karin et al., 2002). A wide
range of stimuli, including cytokines and viral and bacterial prod-et al., 1997). Immune and inflammatory cells and their secreted
chemokines and cytokines have dramatic effects both on the ucts, activate NF-B, mostly through IB kinase (IKK)-depen-
dent phosphorylation and subsequent degradation of specifichost’s physiology and on cancer cell behavior, modulating the
growth, migration, and differentiation of many cell types within inhibitors, the IBs, that retain NF-B in the cytoplasm (Ghosh
and Karin, 2002). Upon activation, NF-B dimers enter the nu-the tumor microenvironment (Coussens and Werb, 2002; Liotta
S I G N I F I C A N C E
NF-B transcription factors play a central role in immune and inflammatory responses. Some NF-B-regulated genes are associated
with tumor progression and metastasis, processes known to be induced by inflammation. Our work explains how NF-B converts
inflammatory stimuli into tumor growth signals and consequently speeds up metastatic tumor growth. Inhibition of NF-B in cancer
cells converts inflammation-induced tumor growth to inflammation-induced tumor regression. While the first response is mediated
by TNF, the second response is mediated by TRAIL. Our results suggest that inhibition of NF-B in cancer cells can strongly potentiate
the efficacy of TRAIL or TRAIL inducers in cancer therapy.
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Figure 1. NF-B inhibition converts LPS-induced
tumor growth to tumor regression
A: Establishment of an NF-B-deficient cell line.
Mouse colon adenocarcinoma CT26 cells were
stably transfected with either an empty vector or
a vector encoding the IB(AA) super-repressor.
Cells were stimulated with TNF (10 ng/ml), and
expression of endogenous IB and IB(AA)
was analyzed by immunoblotting. NF-B DNA
binding activity was examined by EMSA.
B: NF-B inhibition results in LPS-induced tumor
regression. 1  105 cells (CT, CT/vector, or CT/
IB[AA]) were injected into mice that after 9
days were administered PBS (vehicle) or LPS.
Seven days later, mice were sacrificed and lungs
were removed, weighed, and photographed,
and the numbers of tumor nodules detectable
on the lung surface were determined and statisti-
cally analyzed (*, p  0.05; **, p  0.01).
C: Histology of lung metastatic tumors. Tumors
generated by injection of the indicated cell lines
were exposed to PBS (vehicle) or LPS in vivo, and
7 days later the lungs were removed, formalin
fixed, sectioned, and H&E stained. Magnifica-
tion: 10.
cleus, where they modulate transcription of many genes encod- al., 2002; Pidgeon et al., 1999), and demonstrated that NF-B
activation in cancer cells is responsible for inflammation-induceding cytokines, growth factors, cell adhesion molecules, and anti-
apoptotic proteins. Some NF-B-regulated gene products, tumor growth. Importantly, inhibition of NF-B converts LPS-
induced tumor growth to LPS-induced tumor regression. Weincluding those encoding intercellular adhesion molecule 1
(ICAM-1), the extracellular matrix protein tenascin C, vascular found that the mediators through which LPS induces these
opposite outcomes are TNF and TRAIL, respectively. Our re-endothelial growth factor (VEGF), the chemokine IL-8 and its
mouse homologs, the proinflammatory enzyme cyclooxygenase sults suggest a novel strategy for cancer therapy, based on
combining the inhibition of NF-B in cancer cells with induction2 (COX2), and matrix metalloprotease 9 (MMP9), are associated
with tumor progression and metastasis (Coussens and Werb, of TRAIL, by the host immune system.
2002; Karin et al., 2002). Thus, it seems that NF-B can convert
inflammatory stimuli into tumor growth signals. However, NF-B Results
may also control the expression of apoptosis-promoting cyto-
kines (death cytokines) such as TNF (Zhu et al., 2000) and NF-B activation is required for LPS-induced
FAS ligand (FASL) (Kasibhatla et al., 1998). Nonetheless, the tumor growth
ability of NF-B to inhibit apoptosis appears to be stronger We modified a murine metastasis model in which a mouse colon
than its ability to promote apoptosis (Karin and Lin, 2002), and cancer cell line, CT26, originally induced in BALB/c mice by
exposure to 1,2-dimethylhydrazine, was used to generate lungtherefore, inhibition of NF-B was suggested to be a useful
strategy for cancer therapy (Baldwin, 2001; Karin et al., 2002). metastases (Harmey et al., 2002; Pidgeon et al., 1999) whose
growth is stimulated in response to LPS administration. To ex-Here we modified an experimental murine metastasis model in
which bacterial lipopolysaccharide (LPS), a byproduct of gram- amine the role of NF-B in this process, we transfected CT26
cells with a vector encoding an IB “super-repressor” mutantnegative bacteria, induces metastatic tumor growth (Harmey et
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Figure 2. NF-B inhibition blocks LPS-induced tu-
mor proliferation, enhances LPS-induced tumor
apoptosis, and extends host survival
A: NF-B is required for LPS-induced tumor cell
proliferation. Proliferating cells were identified by
BrdU labeling and staining with anti-BrdU anti-
body (brown). The tissue was counterstained
with hematoxylin (blue).
B: NF-B inhibition results in LPS-induced tumor
cell death. Apoptotic cells were identified by
TUNEL staining (green).
C: NF-B inhibition extends host survival. Kaplan-
Meier survival analysis of CT/vector-, CT/IBAA-
tumor-bearing mice challenged with either LPS
or PBS, as described above. The time (days) rep-
resents mouse survival time after tumor inocula-
tion at day 0.
(IB[AA]) that is resistant to stimulus-induced degradation (Di- To rule out the possibility that the data obtained above could
be the result of nonspecific clonal variation rather than speci-Donato et al., 1996) or an “empty” vector as a control. Expres-
sion of endogenous IB in CT/IB(AA) cells was inhibited, fic NF-B inhibition, we repeated the above experiments by
using another CT/IB(AA) clone (Clone 2), as well as a clonedand induction of NF-B DNA binding activity by TNF was
abolished (Figure 1A). The different cell lines (CT, CT/vector, or cell line (4T1/IB[AA]) derived from the breast cancer cell line
4T1 by stable transfection with the IB(AA)-expression plas-CT/IB[AA]) were introduced into BALB/c mice, which after 9
days were injected intraperitoneally (i.p.) with LPS in PBS or mid. Using both cell lines, we obtained very similar results to
those described above (Supplemental Table S1 at http://www.PBS alone. Seven days later, mice were sacrificed, and their
lungs were removed and weighed, the tumor nodules on the cancercell.org/cgi/content/full/6/3/297/DC1). We also found
that LPS challenge could remarkably decrease the size of tu-lung surface were counted, and the tumor-bearing lung tissues
were microscopically examined. We used both total lung weight mors formed by subcutaneous inoculation of BALB/c mice with
CT26 carcinoma cells whose NF-B activity was inhibited withand the number of tumor nodules visible on the lung surface
to evaluate lung tumor burden. Both tumor nodule numbers and the IB super-repressor (Supplemental Figure S1 and data not
shown).lung weights in the LPS-challenged CT and CT/vector groups
were significantly (p  0.05) higher than in the vehicle controls Next, we asked whether the LPS-induced changes in lung
tumor burden were due to altered cell proliferation or apoptosis.(Figure 1B). By contrast, administration of LPS to the CT/
IB(AA) group resulted in a significant (p  0.05) decrease in Tumor cells were injected into mice and LPS or PBS was admin-
istered as above. After 22.5 hr, the mice were pulsed with 5-bro-lung weight and in tumor nodule numbers (Figure 1B). There
were no significant differences in lung tumor burdens between modeoxyuridine (BrdU) and sacrificed. BrdU incorporation,
which identifies cells undergoing DNA synthesis, was examinedthe CT, CT/vector, and CT/IB(AA) groups after PBS adminis-
tration. Microscopic examination of paraffin-embedded lung by staining with anti-BrdU antibody. Apoptotic cells were identi-
fied by in situ terminal-transferase dUTP-mediated nick end-sections excluded the possibility that the gain in lung weight
was due to edema or hemorrhage (Figure 1C). In addition, the labeling (TUNEL) assay. Consistent with the changes in lung
tumor burden, BrdU incorporation was much higher in LPS-histological examination confirmed the massive reduction in
tumor load in mice harboring CT/IB(AA) tumors that were challenged CT and CT/vector-generated tumors than in tumors
of the same type exposed to PBS alone (Figure 2A and datatreated with LPS.
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not shown). By contrast, BrdU incorporation into CT/IB(AA)
tumors was reduced after LPS administration. Conversely, the
extent of apoptosis was dramatically increased after LPS-treat-
ment of CT/IB(AA) tumors, whereas very little apoptosis was
seen after LPS treatment of CT or CT/vector tumors (Figure 2B
and data not shown). The basal levels of cell proliferation and
apoptosis in PBS-treated tumors of all three cell types were
quite similar. Thus, inhibition of NF-B activity in cancer cells
converts the LPS-induced proliferative response to an apoptotic
response.
We also examined the survival times of mice harboring CT/
vector and CT/IB(AA) metastatic lung tumors that were chal-
lenged with either LPS or PBS alone using Kaplan-Meier survival
analysis. We found that LPS administration shortened the life
span of CT/vector tumor-bearing mice, but prolonged the sur-
vival time of CT/IB(AA) tumor-bearing mice (Figure 2C). There
were no differences in the survival rates of mice bearing either
CT/vector or CT/IB(AA) tumors that received PBS alone.
These results are consistent with those obtained by measuring
lung nodule numbers, total lung weight, or lung histology.
LPS induces NF-B-dependent genes in tumor cells
To examine how NF-B activation mediates LPS-induced tumor
growth, we analyzed expression of NF-B target genes known
to be involved in cell proliferation and apoptosis (Karin et al.,
2002; Karin and Lin, 2002). Tumors were established as above,
and 24 hr after administration of LPS or PBS, the mice were
sacrificed. Tumor tissue was microdissected, lysed, and ana-
lyzed by immunoblotting and zymography. Expression of the
antiapoptotic proteins Bcl-XL, cIAP1, and cIAP2 (Figure 3A) as
well as MMP9 activity (Figure 3B), were strongly induced in
response to LPS treatment in CT and CT/vector tumors, but Figure 3. LPS induces NF-B-dependent expression of antiapoptotic and
prometastatic genes in tumor cellsnot in CT/IB(AA)-generated tumors. The failure to induce anti-
apoptotic proteins may explain the apoptotic response to LPS A: Expression of NF-B-dependent genes in tumor cells. Tumors generated
by injection of the indicated cell lines were exposed to PBS or LPS in vivoseen after inhibition of NF-B. Expression of MMP9, on the
and isolated 24 hr later. Tumor cell lysates were analyzed by immunoblottingother hand, is likely to affect tumor invasiveness and growth.
for expression of the indicated proteins.We also found that expression of PCNA, an S phase marker, B: Induction of MMP activity in tumor cells. Tumor cell lysates generated as
correlated with the NF-B activation state of the cells being above were analyzed by zymography on gels copolymerized with gelatin
or casein/plasminogen to detect MMP activity. This figure shows a gelatin-high in CT and CT/vector tumors from LPS treated mice and
containing gel. The locations of the indicated MMPs were identified bylow in CT/IB(AA) tumors (Figure 3A). These results correlate
negative staining.with those obtained by the analysis of BrdU incorporation (see
Figure 2A).
TNF mediates LPS-induced tumor growth mice (Figure 4C). Thus, NF-B activation in tumors requires
and NF-B activation functional TLR4 in one of the host cell types, possibly a macro-
Activation of NF-B by LPS requires Toll-like receptor 4 (TLR4), phage whose infiltration into tumors was enhanced after LPS
a cell surface receptor that is mostly expressed on myeloid cells challenge (Supplemental Figure S2 at http://www.cancercell.
(Poltorak et al., 1998). We examined whether LPS activated NF- org/cgi/content/full/6/3/297/DC1).
B in CT26 cells through a direct mechanism or via a myeloid These findings suggested that a LPS-induced inflammatory
cell intermediate. Although direct incubation with LPS activated mediator produced by host cells is responsible for NF-B activa-
NF-B in CT26 cells in vitro, rather high doses of LPS were tion in tumors. A major proinflammatory cytokine whose produc-
required (Figure 4A). The low sensitivity to LPS could be due tion is strongly induced by LPS is TNF (Tracey and Cerami,
to low TLR4 mRNA expression in CT26 cells relative to macro- 1994). Indeed, LPS administration to tumor-bearing WT mice
phages (Figure 4B). To determine if TLR4 in host cells is required resulted in rapid and robust induction of circulating TNF (Figure
for NF-B activation in CT26 tumors, we inoculated wild-type 4D). Administration of an anti-TNF antibody 5 min after LPS
(WT) mice as well as Tlr4Lps-d mutant mice, which express a challenge neutralized most of the circulating TNF (Figure 4E).
signaling defective form of TLR4 (Poltorak et al., 1998), with NF-B activation by LPS was similar in its kinetics to TNF
CT26 cells. Tumor-bearing mice were administered LPS as de- release and was inhibited by the neutralizing anti-TNF antibody
scribed above, and NF-B activation in tumors was analyzed (Figure 4F). Similar results were obtained by staining tumor
2 hr later. Whereas LPS induced NF-B activation in tumors tissue with anti-RelA(p65) antibody (Supplemental Figure S3).
LPS administration induced the nuclear appearance of phos-grown in WT mice, it failed to do so in tumors grown in Tlr4lps-d
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Figure 5. TNF mediates LPS-induced tumor growth but not LPS-induced
tumor regression
A and B: TNFmediates LPS-induced tumor growth. Mice reconstituted with
WT, Tnfr1/, or Tnf/ bone marrow were inoculated with CT26 tumor cells
and after 9 days were administered PBS or LPS. Seven days later, the lungs
were removed and weighed (A), and the tumor nodules on the lung sur-
faces were counted (B). (*, p  0.05; **, p  0.01).
C and D: TNF is not required for LPS-induced tumor regression. Mice reconsti-
tuted with WT or Tnf/ bone marrow were inoculated with CT/IBAA
tumor cells and after 9 days were administered PBS or LPS. Seven days later,
the lungs were removed and weighed (C), and tumor nodules on the lung
surfaces were counted (D) and statistically analyzed. (*, p  0.05; **, p 
0.01).Figure 4. TNF mediates LPS-induced NF-B activation in tumors
A: Activation of NF-B in cultured cells. CT26 cells were treated with different
doses of LPS (in g/ml) or TNF (10 ng/ml). NF-B and NF1 DNA binding
activities were determined by EMSA.
B: TLR mRNA expression. RNA was isolated from the indicated tumor cells the lungs were removed and weighed and tumor nodules on
or bone marrow-derived macrophages and analyzed by semiquantitative the lung surfaces were counted. The lung tumor burdens in
RT-PCR for expression of TLR2 and TLR4 mRNAs.
chimeric mice reconstituted with either WT or Tnfr1/ boneC: LPS is an indirect activator of NF-B in tumors. Tumor-bearing mice (WT and
Tlr4lps-d) were administered LPS as described above. Tumors were collected 2 marrow were significantly increased after LPS challenge (Fig-
hr later, and NF-B and NF1 DNA binding activities were examined by EMSA. ures 5A and 5B). However, no LPS-induced increase in tumor
D: LPS induces release of circulating TNF. CT26 tumor-bearing mice were
burden was evident in lungs from mice reconstituted withinjected with LPS. and serum samples were collected at the indicated time
Tnf/ bone marrow. Similar results were obtained by measur-points. TNF concentration was determined by ELISA.
E: Neutralization of circulating TNF. Tumor-bearing mice were injected with ing NF-B DNA binding activity in tumor tissues: while LPS
LPS, and 5 min later were injected with 30 l of anti-TNF antibody (AF-410- caused NF-B activation in tumors grown in WT or Tnfr1/
NA, Pharmingen) or PBS. Serum was collected after 2 hr, and TNF level
chimeric mice, no such induction was seen in Tnf/ chimericwas determined by ELISA.
mice (data not shown). Thus, TNF production by host hemato-F: Activation of NF-B is TNF-dependent. Tumor-bearing mice were adminis-
tered LPS without or with anti-TNF antibody as described above. Tumors poietic cells is required for activation of NF-B in cancer cells
were collected at the indicated time points, and NF-B DNA binding activity and stimulation of tumor growth.
was examined by EMSA.
TRAIL mediates LPS-induced regression
of NF-B-deficient tumors
In addition to prevention of LPS-induced tumor growth, inhibi-phorylated RelA. This response was blocked by the IB super-
tion of NF-B activity in CT26 cells converted the growth re-repressor. We conclude that TNF is the main mediator through
sponse to a death response. We therefore searched for thewhich LPS activates NF-B in tumors.
mediator through which LPS induces the apoptotic response.We examined whether ablation of TNF production or sig-
We first suspected that TNF may be this mediator, as it wasnaling prevents LPS-induced NF-B activation and tumor
shown that high doses of TNF can kill tumor cells when NF-Bgrowth. Bone marrow from WT, type 1 TNF receptor-deficient
activity is inhibited (Wang et al., 1999). We therefore generated(Tnfr1/), or TNF-deficient (Tnf/) mice was individually
either WT or Tnf/ chimeric mice and inoculated them with CT/transplanted into lethally irradiated BALB/c mice to generate
IB(AA) tumor cells. Curiously, LPS administration decreasedchimeric mice, which were inoculated six weeks later with CT26
tumor cells. LPS or PBS were administered, and 7 days later tumor burden to a similar extent in both WT and Tnf/ radiation
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Figure 6. TRAIL mediates LPS-induced tumor re-
gression
A: LPS-induced expression of proapoptotic mole-
cules. Mice bearing CT/vector or CT/IB(AA) tu-
mors were administered LPS or PBS. After 12 hr,
the mice were sacrificed, and tumors were care-
fully microdissected using needles to avoid
blood contamination from one of the lungs,
whereas the other lung was left as is. RNA was
isolated and gene expression was analyzed by
RNase protection assay.
B: LPS-induced TRAIL protein expression. Mice
bearing CT/vector or CT/IB(AA) tumors were
administered LPS or PBS. After 14 hr the mice
were sacrificed, and tumors were microdis-
sected from one of the lungs, whereas the other
lung was left as is. Protein was isolated and TRAIL
expression was examined by immunoblotting.
C: TRAIL mediates LPS-induced tumor regression.
Mice bearing CT/IB(AA) tumors were adminis-
tered PBS or LPS. Thirty minutes before and 3 days
after the LPS challenge, mice were i.p. injected
with either anti-TRAIL monoclonal antibody or a
control IgG2a (300 g each). Seven days after
LPS injection, mice were sacrificed and their
lungs removed, weighed, and photographed,
and tumor nodules on the lung surface were
counted and statistically analyzed. (*, p  0.05;
**, p  0.01).
D: TRAIL blockade prevents LPS-induced cell
death. Apoptotic cells were identified by TUNEL
staining (green).
chimeras (Figures 5C and 5D). Thus, TNF is not a critical media- To examine the role of TRAIL, mice bearing CT/IB(AA)
tor of LPS-induced regression of NF-B-deficient tumors. tumors were i.p. injected with a neutralizing anti-TRAIL antibody
To search for other death mediators induced by LPS, we (Takeda et al., 2001) or a control IgG2a 30 min before and
examined expression of TNF family members, their receptors, 3 days after LPS challenge. After seven days, the mice were
and effector molecules in microdissected tumor cells and tumor- sacrificed and their lungs were removed, microscopically exam-
bearing lungs. We observed that both TRAIL and FAS mRNAs ined, and weighed, and tumor nodules on the lung surface
were strongly induced in tumor-bearing lung tissue, but not in were counted. LPS challenge of mice treated with control IgG2a
microdissected tumor cells after LPS challenge (Figure 6A). We resulted in a markedly reduced tumor burden, and injection of
also observed weak induction of the mRNAs for FASL and anti-TRAIL antibody completely blocked this effect (Figure 6C
downstream effectors of apoptosis such as RIP1 and caspase
and Supplemental Figure S4 at http://www.cancercell.org/cgi/8. As FAS is not expressed by CT26 tumors (Chen et al., 1998),
content/full/6/3/297/DC1). A TUNEL assay demonstrated thatit is rather unlikely that FASL is the mediator of LPS-induced
the anti-TRAIL antibody entirely ablated the apoptotic responsetumor regression. A more likely candidate was TRAIL, whose
of NF-B-deficient tumors to LPS stimulation (Figure 6D). Thesereceptor DR5 (Ashkenazi and Dixit, 1998) was expressed by
results strongly suggest that TRAIL is the main effector thatmicrodissected tumor cells (see Figure 7D). Consistent with the
mediates LPS-induced death and regression of NF-B-deficientmRNA expression data, the levels of TRAIL protein were highly
tumors.elevated following LPS administration in tumor-bearing lung
tissues, but not in microdissected tumor cells (Figure 6B). Expression of TRAIL is induced by type I and type II interfer-
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Figure 7. LPS induces TRAIL expression on NK cells
and DR5 expression in NF-B-deficient tumor cells
A: LPS induces IFN and IFN gene expression.
Tumor-bearing mice were exposed to PBS or LPS,
and tumor-bearing lung tissues were removed
6 hr later for RNA extraction and real-time PCR
analysis.
B: Enhanced p53 phosphorylation correlates with
increased JNK activation. Tumor-bearing mice
were injected with PBS or LPS, and tumors were
microdissected from isolated lungs 24 hr later.
Tumor cell lysates were examined by immu-
noblotting for expression and phosphorylation of
the indicated proteins.
C: TRAIL induction in NK cells. Tumor-bearing
mice were injected with LPS, IFN, and IFN or
PBS, and tumor-bearing lung tissues were re-
moved 4 hr (IFN, and IFN injection) or 12 hr
(LPS injection) later for isolation of mononuclear
cells. TRAIL expression on NK cells was analyzed
by flow cytometry after double staining of mono-
nuclear cells with anti-NK cell and anti-TRAIL anti-
bodies. The results show the level of anti-TRAIL
staining in cells stained positively by anti-NK.
D: Upregulation of DR5 in CT/IB(AA) tumors.
Tumor-bearing mice were injected with PBS or
LPS. Tumors were isolated 12 hr later for RNA ex-
traction, and DR5 expression was examined by
RT-PCR.
ons (IFNs) (Smyth et al., 2003). LPS is known to activate the 1999) to investigate the mechanism through which a strong
proinflammatory stimulus, such as the one provided by LPS,IFN signaling pathway (Hsu et al., 2004). Indeed, administration
of LPS resulted in induction of IFN and IFN mRNAs in tumor- a component of gram-negative bacteria, can stimulate tumor
growth. It has been reported that bacterial contamination duringbearing lung tissues (Figure 7A) and led to activation of the
IFN-responsive transcription factor STAT1 in isolated lung tumor surgery or postoperative inflammation can increase metastatic
tumor growth in both mice (Harmey et al., 2002; Pidgeon et al.,cells (Figure 7B). It has been reported that TRAIL is constitutively
expressed on murine natural killer (NK) cells in the liver and 1999) and human patients (Taketomi et al., 1997). Our results
indicate that the major inflammatory mediator responsible forplays a substantial role in suppressing tumor metastasis (Takeda
et al., 2001). We examined TRAIL expression levels on NK cells LPS-induced tumor growth is TNF. Although TNF was so
named after its ability to induce tumor death (Palladino et al.,in tumor-bearing lung tissues by flow cytometry and found that it
was induced by either LPS, IFN, or IFN challenge (Figure 7C). 2003), in this model of metastatic colon adenocarcinoma, TNF
does not act as a death mediator, but is responsible for in-LPS injection also led to activation of JNK1, and consistent
with earlier findings (Tang et al., 2001), JNK activation, which creased tumor growth. Although high doses of TNF adminis-
tered in close proximity to solid tumors can kill both canceraugments apoptosis, was potentiated by inhibition of NF-B
(Figure 7B). Increased JNK activity in CT/IB(AA) tumors corre- cells and the tumor neovasculature, there is also growing evi-
dence that endogenous TNF promotes tumor developmentlated with increased phosphorylation of p53 at serine 15, a
putative JNK phosphorylation site (Fogarty et al., 2003). CT26 and growth (Moore et al., 1999; Wilson and Balkwill, 2002). In
our case, the growth-promoting activity of TNF is dependentcells express WT p53 (unpublished data), whose increased
phosphorylation may account for the modest elevation in ex- on NF-B activation, but the inhibition of NF-B is not sufficient
for rendering CT26 tumors susceptible to TNF-induced apo-pression of the cell cycle inhibitor p21 (Figure 7B), and the
ptosis. Nonetheless, NF-B in CT26 cells is responsible formore remarkable induction of DR5 mRNA in CT/IB(AA) tumors
induction of several antiapoptotic proteins, including Bcl-XL,(Figure 7D). Both DR5 and p21 are encoded by p53 target genes
cIAP1, and cIAP2. Most importantly, the inhibition of NF-B(Fei et al., 2002; Wu et al., 1997).
in CT26 cells converted the growth-promoting effect of LPS,
mediated by TNF, to a cytocidal effect. That effect of LPS wasDiscussion
found to be mediated by TRAIL rather than by TNF. These
results are not unique to CT26 colon carcinoma cells, and inhibi-In the present study, we used a modified version of an experi-
mental metastasis model (Harmey et al., 2002; Pidgeon et al., tion of NF-B activity in 4T1 mammary carcinoma cells, which
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2  105/ml. Only single-cell suspensions of greater than 90% viability basedalso grow faster as lung metastasis in response to LPS (Harmey
on Trypan Blue exclusion were used. Six-week-old mice were injected withet al., 2002), converts the LPS induced growth response to a
either 105 CT or 5  104 4T1 cells via the tail vein. Nine days later, micetumor regression response (Supplemental Table S1).
were injected i.p. with 10 g LPS (serotype 055:B5; Sigma Chemical, St.
TRAIL, also known as Apo2 ligand, is a type II transmem- Louis, MO) in PBS or PBS alone. After seven days, mice were sacrificed,
brane protein of the TNF family, which preferentially induces and lungs were removed, weighed, and histologically examined. When indi-
cated, 300 g of either anti-TRAIL mAb (Takeda et al., 2001) or control ratapoptosis in a variety of transformed cells but not in normal
IgG2a (Pharmingen) were injected i.p., once 30 min before and once 3 dayscells (Ashkenazi, 2002). Unlike TNF, TRAIL is a weak inducer
after LPS challenge. For protein and RNA analysis, lung tumor nodules wereof inflammation (Song et al., 2000), an important property which
microdissected using an 18 G needle under a microscope. Alternatively, theis probably related to its poor NF-B activating ability (Ashkenazi
entire tumor-bearing lung was used.
et al., 1999). Administration of recombinant TRAIL suppresses
the growth of tumor xenografts with no apparent systemic toxic- Chimeric mice
Single-cell suspensions of bone marrow from WT, Tnf/, or Tnfr1/ miceity (Ashkenazi et al., 1999; Walczak et al., 1999). Endogenously
were prepared, and 5  105 cells were injected into the tail vein of 6-week-expressed TRAIL on the surface of NK cells plays a critical role
old BALB/c female hosts that were exposed to 900 rad of  radiation. Hostin suppression of liver and lung metastases (Smyth et al., 2001;
mice were maintained under sterile conditions, using autoclaved cages,
Takeda et al., 2001). Our results demonstrate that LPS challenge food, and water containing 25 mg/l neomycin sulfate and 13 mg/l polymyxin
leads to upregulation of TRAIL expression in the tumor microen- B sulfate (Senftleben et al., 2001).
vironment, which may be mainly derived from NK cells and
Histological proceduresmacrophages, where it is induced by type I and type II IFNs
Dissected tumors or entire lungs were immersed in 10% neutral buffered(Smyth et al., 2003). In addition to preventing the expression of
formalin before sectioning. Sections were stained with Harris haematoxylinantiapoptotic proteins, inhibition of NF-B also led to increased
and eosin (H&E) and BrdU- and TUNEL-positive cells were identified as
expression of the TRAIL receptor DR5, thereby making a dual described (Cao et al., 2001).
contribution to increased TRAIL sensitivity. Induction of DR5
could be due to potentiation of JNK activation caused by inhibi- Analysis of gene expression
Nuclear protein extracts were prepared from tumor cells, and NF-B DNAtion of NF-B (Tang et al., 2001). JNK can phosphorylate p53 at
binding activity was measured by electrophoretic mobility shift assay (EMSA)serine 15, thereby increasing the p53-mediated transcriptional
as described (Senftleben et al., 2001). Total tissue RNA was prepared usingresponse (Fogarty et al., 2003), which includes DR5 among its
the RNAeasy kit (Qiagen, Valencia, California). For RNase protecton assay
targets (Fei et al., 2002). (RPA), RNA was hybridized overnight at 56	C to 2 106 c.p.m. of 32P-labeled
In addition to TNF and TRAIL, other cytokines may also probes corresponding to mouse multiprobe template set mAPO (Phar-
Mingen) and analyzed as described (Makris et al., 2000). RT-PCR was per-effect tumor progression or regression. A considerable effort
formed as described (Senftleben et al., 2001). Immunoblotting, immunohisto-has been invested in the use of cytokines in cancer therapy
chemistry, or flow cytometry (Senftleben et al., 2001; Cao et al., 2001) were(Dranoff, 2004). In addition to TRAIL, a tumoricidal effect has
applied using antibodies to IB, PCNA, JNK1, NK cells (all from Phar-
also been obtained with type I and type II IFNs (Dranoff, 2004), mingen), cIAP1 (kindly provided by Dr. C. Duckett, NIH), Bcl-2 (Transduction
which as discussed above are efficient inducers of TRAIL. How- Labs), Integrin4 (Chemicon), actin (Sigma), p21, Bcl-XL, cIAP2, STAT1,
ever, IFN-induced immune toxicity has been a limiting factor TRAIL (all from Santa Cruz Biologicals), phospho-p65, phospho-JNK, phos-
pho-p53, or phospho-STAT1 (all from Cell Signaling). TNF concentrationsthat restricts the amount of IFN that can be used for effective
in serum were determined by ELISA as recommended by the manufacturercancer therapy (Gutterman, 1994). Some of the IFN-induced
(Quantikine, R&D Systems, Minneapolis, Minnesota). Zymography for MMPstoxicities could be TNF-mediated. As TNF does not make a
was performed as described (Daniels et al., 2003).
major contribution to tumor killing and instead may promote
tumor growth, we postulate that it may be advisable to combine Statistical analysis
The data were analyzed by unpaired Student’s t test (2-tailed) or Kaplan-IFN-based therapy with anti-TNF drugs, which may reduce
Meier survival analysis. Data were taken to be significant when p  0.05.inflammation-associated toxicities, block inflammation-induced
tumor growth, and potentiate TRAIL-dependent tumor killing.
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